TARGETING TETRASPANIN 7 TO DEVELOP NEW DRUGS FOR OSTEOCLAST-RELATED BONE DISEASES
Keywords:
drug target, osteoclast-related bone disease, TSPAN7 peptide inhibitor, TSPAN7-FcAbstract
INTRODUCTION
Bone remodeling is essential for bone homeostasis and is controlled by bone-forming osteoblasts and bone-resorbing osteoclasts. Several bone diseases, including osteoporosis, are related to an imbalance of activity between the 2 cell types. Previous results from our group and others have shown that tetraspanin 7 (TSPAN7) plays an important role in cytoskeletal reorganization and bone resorption in osteoclasts. In this study, we investigated the efficacy of TSPAN7 as a potential new drug target for osteoclastrelated bone diseases.
METHODOLOGY
We constructed soluble cell-permeable TSPAN7-NT and -CT peptide inhibitors, and TSPAN7-Fc fusion protein that consists of the EC2 domain of TSPAN7 and the Fc part of human IgG (hIgG). The effects of TSPAN7 peptide inhibitors and TSPAN7-Fc on osteoclasts were evaluated by TRAP staining assay, actin ring immunofluorescence assay, and bone resorption assay. The bone-protective effect of TSPAN7-Fc was determined with the pathological bone loss models: lipopolysaccharide (LPS) and ovariectomy (OVX) models. The statistical tests used were the student’s 2-tailed T-test and ANOVA.
RESULTS
In-vitro study showed that both TSPAN7 peptide inhibitors and TSPAN7-Fc inhibited the formation of fully spreading mature osteoclasts with normal actin rings, thereby leading to significantly decreased bone resorption. In addition, mice treated with TSPAN7-Fc were protected against LPSand OVX-induced bone loss. Interestingly, TSPAN7-Fc
induced abnormal morphology of osteoclasts in vivo.
CONCLUSION
Our findings suggest that specific inhibition of TSPAN7 could be used as a novel therapeutic strategy to treat osteoclast-related bone diseases.
Downloads
References
*
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Minhee Kim, Soo Young Lee
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.